Loading IQV detail
Loading ticker data...
Loading IQV detail
IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with HealthCore, Inc. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.
IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.
Chart data unavailable
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IQVIA's AI push with NVIDIA, strategic deals and buybacks drive growth, but weakening liquidity raises concerns over near-term financial flexibility.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SG Americas Securities LLC grew its stake in IQVIA Holdings Inc. (NYSE: IQV) by 108.8% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,206 shares of the medical research company's stock after purchasing an additional 26,161 shares during the period.
Eagle Rock Investment Company LLC boosted its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 30.4% in the undefined quarter, according to its most recent Form 13F filing with the SEC. The fund owned 60,416 shares of the medical research company's stock after purchasing an additional 14,084 shares during the period.
Shares of IQVIA Holdings Inc. (NYSE: IQV - Get Free Report) have been assigned a consensus rating of "Buy" from the seventeen research firms that are currently covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong
Cullen Investment Group LTD. reduced its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 13.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,941 shares of the medical research company's stock after selling 3,199 shares during the quarter.
Community Trust and Investment Co. trimmed its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 7.9% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 100,312 shares of the medical research company's stock after selling 8,599
Nordea Investment Management AB lessened its holdings in IQVIA Holdings Inc. (NYSE: IQV) by 69.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 713,313 shares of the medical research company's stock after selling 1,600,906 shares during the quarter. Nordea Investment Management AB
Broyhill Asset Management LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE: IQV) by 15.2% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 27,010 shares of the medical research company's stock after buying an additional 3,560 shares during the
Glenmede Investment Management LP reduced its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 8.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 202,711 shares of the medical research company's stock after selling 19,677 shares during
IQVIA Holdings Inc. (IQV) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
IQVIA Holdings Inc. (IQV) Presents at Leerink Global Healthcare Conference 2026 Transcript
Elo Mutual Pension Insurance Co lifted its holdings in shares of IQVIA Holdings Inc. (NYSE: IQV) by 97.1% during the undefined quarter, according to its most recent disclosure with the SEC. The institutional investor owned 29,160 shares of the medical research company's stock after purchasing an additional 14,362 shares during the quarter. Elo
DNB Asset Management AS trimmed its position in shares of IQVIA Holdings Inc. (NYSE: IQV) by 9.0% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 81,265 shares of the medical research company's stock after selling 8,000 shares during the quarter. DNB
